Long-Term AEs Persist in Some Survivors of Testicular Cancer
A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.
Testicular Cancer
One-Cycle BE500P Seems Safe for High-Risk Early Testicular Cancer
Malignant recurrence rate was 1.3 percent at two years for one-cycle BE500P in high-risk early-stage disease.
Testicular Cancer Treatment Regimens
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer
TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.
Twins Study Suggests Strong Familial Risk for Testicular Cancer
A study of twins with 22 980 individuals suggested that the familial risk for testicular cancer may be dramatically underestimated.
Post-chemo Lymph Node Dissection Important for Potentially Curing Patients
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) important for rendering patients with testicular cancer disease-free.
Patients with Testicular Nonseminoma More Likely to Die of Cardiovascular Disease With Chemo
Patients with testicular cancer who received chemotherapy, but not surgery, were more likely to die from cardiovascular disease (CVD).
Study Confirms Excellent Prognosis for Stage I Seminoma
Patients presenting with stage I seminoma who received adjuvant carboplatin following inguinal orchidectomy have excellent prognosis.
Future Mortality Risk Measured by Life Expectancy in Various Cancers
Life expectancy is a significant indicator of future mortality risk and additional care in patients with cancer of the breast, colon and testes.
-
Loading...
-
Loading...
